One-year clinical outcomes of aspirin versus indobufen in patients with NSTEMI: a multicenter retrospective cohort study
Aspirin is the cornerstone of antiplatelet therapy for non-ST-elevation myocardial infarction (NSTEMI), while indobufen serves as an alternative for patients with aspirin intolerance. However, comparative data on their long-term efficacy and safety in real-world NSTEMI populations are limited. This study a...